Auguste Gaddah

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

Andrew J. Pollard, Odile Launay, Jean‐Daniel Lelièvre et al. · The Lancet Infectious Diseases · 2020 · 170 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

David Ishola, Daniela Manno, Muhammed O. Afolabi et al. · The Lancet Infectious Diseases · 2021 · 95 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +13

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

Muhammed O. Afolabi, David Ishola, Daniela Manno et al. · The Lancet Infectious Diseases · 2021 · 93 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

Houreratou Barry, Gaudensia Mutua, Hannah Kibuuka et al. · PLoS Medicine · 2021 · 69 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial

Zacchaeus Anywaine, Houreratou Barry, Omu Anzala et al. · PLoS Medicine · 2022 · 63 citations · Full text

Medicine, Infectious Diseases, Pediatrics +17